NeoX Biotech is a technology company.
NeoX Biotech has raised $30.0M across 1 funding round.
NeoX Biotech has raised $30.0M in total across 1 funding round.
neoX Biotech is a biotechnology company founded in 2018 and headquartered in Beijing, China, that integrates artificial intelligence (AI) with biophysics to accelerate drug research and development (R&D).[1][2][3] It specializes in discovering and developing macromolecular and multispecific drugs, particularly in immuno-oncology, using a platform that characterizes protein-protein interactions to enhance therapeutic outcomes like targeted protein degraders (e.g., NXD02 for T-cell malignancies).[1] The company serves global biomedical firms by collaborating to bolster their R&D pipelines, addressing key challenges in drug discovery such as immune response modulation and toxicity reduction through AI-empowered tools like neoDegrader.[1][2]
Growth momentum includes advancing candidates into clinical trials, such as NXD02 in Phase I for T-cell malignancies as of mid-2024, positioning neoX as an innovator in precision oncology amid rising demand for AI-driven biologics.[1]
neoX Biotech was established in 2018 in Beijing by a team of experts including Dr. Hang Chen, Dr. Chen Li, and Dr. Michael Xiao, who brought deep backgrounds in biopharmaceuticals, AI, and biophysics.[1][2][3] The idea emerged from the need to combine computational AI with biophysical modeling to overcome limitations in traditional drug discovery, particularly for complex multispecific drugs and protein degraders in immuno-oncology.[1][3] Early traction came from developing proprietary platforms like neoDegrader, enabling rapid design of degraders with improved safety profiles, such as mitigating platelet toxicity in candidates like NXD02, which quickly progressed to clinical evaluation.[1]
neoX Biotech rides the wave of AI-biotech convergence, a trend exploding in drug discovery where computational platforms cut development timelines from years to months amid a $100B+ biologics market.[1] Timing is ideal post-2020s AI breakthroughs (e.g., protein folding models), aligning with surging immuno-oncology demand as cancer therapies shift toward degraders over inhibitors for harder-to-treat targets like STAT3-driven tumors.[1] Market forces favoring neoX include China's biotech boom, global funding for AI therapeutics, and regulatory nods for novel modalities, positioning it to influence ecosystems by licensing platforms to pharmas and advancing Asia-led innovation in global oncology pipelines.[1][2]
neoX is poised for expansion with clinical readouts from NXD02 and similar degraders, potentially unlocking partnerships or Series funding to scale immuno-oncology portfolios.[1] Trends like multimodal AI (integrating biophysics with generative models) and degraders supplanting small molecules will propel its growth, especially as T-cell therapies gain traction against solid tumors. Its influence may evolve from R&D enabler to leader in next-gen oncology, amplifying Beijing's role in global biotech—echoing its founding mission to redefine drug discovery through intelligent biophysics.[1][3]
NeoX Biotech has raised $30.0M in total across 1 funding round.
NeoX Biotech's investors include 500 Global, Sky9 Capital, SOSV.
NeoX Biotech has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series A in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $30.0M Series A | 500 Global, Sky9 Capital, SOSV |